UMCD6—an mAb targeting the CD6/CD318 axis—enhances the ability of CD8+T, NK-T, and NK cells to kill breast, prostate, and lung cancer cells, accompanied by robust changes in gene and protein expression of the activating receptor NKG2D and the inhibitory receptor NKG2A [39,50,94]. This evidence concerns the gene CDCP1 and lung cancer.